Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
- Update frequency
- every day
- Average duration
- 26 minutes
- Episodes
- 1069
- Years Active
- 2020 - 2025
S5 - E14 - Remembering Stephen Harrison - colleagues share memories and impressions of an SLD master
The sudden passing on April 23 of our co-founder and colleague Stephen Harrison sent shock waves throughout the global SLD community. This week, Manal Abdelmalek and Naim Alkhouri join …
S5 - E13.6 - One Year Ago: When Global Fatty Liver Day Was #NASHDay 2023
This vault conversation looks back to our coverage of International NASHDay 2023, the predecessor title to this year's Global Fatty Liver Day.
Thursday, June 8 was International #NASHDa…
S5 - E13.5 - MASH And The Elephant Metaphor: Attacking A Multi-Faceted, Complex Disease
This closing conversation introduces two new concepts: the idea that MASH has so many facets that it is comparable to the metaphor of blind people touching an elephant, and the provider…
S5 - E13.4 - A Deeper Dive into Care Challenges and Barriers Affecting MASH Patient Care
Jeff McIntyre uses the discussion between Louise Campbell and Mike Betel as a jumping-off point for discussing some of the larger care challenges and barriers associated with MASH patie…
S5 - E13.3 - Practical Challenges In Patient Care: Role Of GLP-1s And Scanning
This conversation focuses on what happens after or around patient screening, addressing the challenges caused by using GLP-1s and dual incretin agonists to treat concomitant conditions …
S5 - E13.2 - Global Fatty Liver Day 2024 And The Rationale Behind "Act Now. Get Screened."
This conversation centers around the Global Fatty Liver Day 2024 theme and the rationale behind focusing on screening.
It starts with Jeff describing how much has changed in MASLD in the…
S5 - E13.1 - Remembering SurfingMASH Co-Founder Stephen Harrison
On April 23, the global MASLD community lost one of its giants when SurfingMASH Co-founder Stephen Harrison passed away unexpectedly. Co-hosts Louise Campbell and Roger Green and guests…
S5 - E13 - Previewing Global Fatty Liver Day 2024
Fatty Liver Alliance Founder and President Mike Betel and Global Liver Institute Vice President for Liver Programs Jeff McIntyre join Louise Campbell and Roger Green to preview the prem…
S5 - E12.6 - From The Vault: More Different Roles For NITs In MASH
One theme in this week's episode involves different ways to use NITs in drug development and assessing the value of older drugs in MASH. This conversation, from our review of last Septe…
S5 - E12.5 - MASH Drug Development: Combining With Old Drugs And Shortening Time To Approval
This wrap-up conversation about MASH Drug Development covers two issues: combination therapies with old drugs and using NITs to speed and smooth the path to approval.
Louise Campbell sta…
S5 - E12.4 - MASH Drug Development: Implications Of Concomitant Metabolic Therapy Use
This conversation starts by focusing on the impact of concomitant metabolic therapies in MASH drug development and patient treatment and then moves on to explore some major implications…
S5 - E15.3 - MASH Drug Development: Improvement Since 2020 And Issues That Remain
This conversation includes two sections: one optimizing efficacy endpoints to reflect clinical practice and a second looking back at what has improved in MASH drug development since 202…
S5 - E12.2 - MASH Drug Development: Improving Efficacy Endpoints
In this conversation, the panel discusses challenges in MASH Drug Development that are centered around efficacy endpoints and NAS scoring.
This conversation starts with Will Alazawi sugg…
S5 - E12.1 - MASH Drug Development: The State Of The Graveyard 2023
In this initial conversation, Sven Francque shares some of the key messages from the MASH Drug Development graveyard paper he co-authored in 2023. Jörn Schattenberg and Will Alazawi com…
S5 - E12 - MASH Drug Development: What Failures Taught Us About Success
In this conversation, Sven Francque and William Alazawi join Jörn Schattenberg, Louise Campbell, and Roger Green to review papers co-authored by Sven in 2023 and Jörn in 2020 to discuss…
S5 - E11.6 - From The Vault: Another Strategic Role For Prescribing MASH Drugs
Earlier in this episode, the panel discusses different prescribing models for MASH drugs, triggered by Roger Green's question about whether MASH prescribing will resemble an oncology mo…
S5 - E11.5 - MASH Prescribing Models & The Increasing Challenge Of Keeping Patients In Long-Term Clinical Trials
This final conversation starts by considering prescribing models for other diseases and how they might work here, shifts to discussing the challenges of keeping a patient enrolled in a …
S5 - E11.4 - More Hot MASLD Topics: Inflammation, MD columnists' Advice, FGF-21s
This conversation sees the end of the "hot topics" discussion, followed by Michael Charlton discussing issues and excitement around the FGF-21 class.
As we begin, Louise Campbell and Jör…
S5 - E11.3 - Panelists' Hot Topics: Low-Dose Aspirin, SLD Think Tank, Dietary Inflammation Index
After Michael Charlton finishes discussing research he finds compelling, Jörn Schattenberg and Louise Campbell each describe one item they have been focusing on recently.
Michael mentio…
S5 - E11.2 - Defining Therapeutic Futility For Rezdiffra And Discussing Advances In MASLD Translational Medicine
Michael Charlton and the Surfers discuss two issues: defining therapeutic futility for Rezdiffra and describing some advances in MASLD translational medicine.
The conversation starts by…